Possibilities of antihypertensive therapy with a drug based on small interfering ribonucleic acid
Inadequate blood pressure control is one of the main causes of cardiovascular complications. This problem remains pressing, in part due to low adherence to therapy associated with complex regimens. This has led to attempts to find new solutions, including the development of agents that do not require frequent administration and can be used to enhance the antihypertensive effect in addition to existing oral medications. Currently, the potential for treating hypertension with an injectable drug based on small interfering ribonucleic acid called zilebesiran is being actively studied. Its antihypertensive effect is associated with the suppression of hepatic angiotensinogen production and a corresponding reduction in angiotensin II levels. In a clinical trial, a single subcutaneous administration of zilebesiran resulted in a significant reduction in blood pressure, with the effect lasting for up to 6 months. This article reviews the literature on this new antihypertensive drug.